Boundless BioBOLD +1.99%14 Quick Ratio is 9.87 as of Mar. 2026, which is 28% below its 10-year median of 13.68. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Boundless Bio ranks better than 78.04% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Boundless Bio's quick ratio for the quarter that ended in Mar. 2026 was 9.87.
Boundless Bio has a quick ratio of 9.87. It generally indicates good short-term financial strength.
The historical rank and industry rank for Boundless Bio's Quick Ratio or its related term are showing as below:
BOLD'
s Quick Ratio Range Over the Past 10 Years
Min: 8.74 Med: 13.68 Max: 22.15
Current: 9.87
During the past 5 years, Boundless Bio's highest Quick Ratio was 22.15. The lowest was 8.74. And the median was 13.68.
BOLD's Quick Ratio is ranked better than 78.04% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs BOLD: 9.87
Boundless Bio (NAS:BOLD) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Boundless Bio Quick Ratio Related Terms
Boundless Bio Quick Ratio Historical Data
* Premium members only.
The historical data trend for Boundless Bio's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Boundless Bio's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boundless Bio Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Boundless Bio's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Boundless Bio's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Boundless Bio's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boundless Bio (BOLD) has a Quick Ratio of 9.87 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Boundless Bio and its competitors. This is 28% below median its historical median of 13.68. Over the past decade, Boundless Bio's Quick Ratio has ranged from 8.74 to 22.15. According to the industry distribution chart, Boundless Bio ranks #311 out of 1416 companies in the Biotechnology industry, placing it in the top 22%.
Is Boundless Bio's Quick Ratio too high?
Boundless Bio's current Quick Ratio of 9.87 is 28% below median its 10-year median of 13.68. Over the past 10 years, this metric has ranged from a low of 8.74 to a high of 22.15. The Biotechnology industry median Quick Ratio is 3.60. Boundless Bio's value of 9.87 is 174.2% above this industry median. Based on the distribution chart, Boundless Bio ranks #311 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Quick Ratio compare to PLRZ and TVRD?
According to the Biotechnology industry distribution chart, Boundless Bio ranks #311 out of 1416 companies for Quick Ratio. This places Boundless Bio in the top 22% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Boundless Bio's value of 9.87 is 174.2% above this benchmark. Historically, Boundless Bio's own Quick Ratio has ranged from 8.74 to 22.15 over the past decade. While the company's 10-year median is 13.68 vs. the industry median of 3.60, Boundless Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boundless Bio's current Quick Ratio of 9.87 is 174.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Boundless Bio and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boundless Bio's current Quick Ratio is 9.87, which is 28% below median its own 10-year median of 13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Quick Ratio of 9.87. The current Quick Ratio is 9.87, which is 28% below median its 10-year median of 13.68 and 174.2% above the Biotechnology industry median of 3.60. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Quick Ratio is 9.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score
Get the complete analysis for BOLD
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLD has been successfully added to your 
